A Bioluminescent transposon reporter-trap identifi es tumor-specifi c microenvironment-induced promoters in salmonella for conditional bacterial-based tumor therapy

Cancer Discovery

Volumn 2, Issue 7, 2012, Pages 624-637

  Flentie, Kelly ^a,b   Kocher, Brandon ^a,b   Gammon, Seth T ^b   Novack, Deborah V ^a   McKinney, Jeffrey S ^a   Piwnica Worms, David ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANAL MONOOXYGENASE (FMN LINKED); GENOMIC DNA; LUCIFERIN; TRANSPOSASE; VEROTOXIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MEGADOSE; GENE ACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HISTOLOGY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALMONELLA; SALMONELLA TYPHIMURIUM; SINGLE DRUG DOSE; TRANSPOSON; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; DNA TRANSPOSABLE ELEMENTS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, BACTERIAL; GENETIC THERAPY; HCT116 CELLS; HELA CELLS; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICE, NUDE; NEOPLASMS; PROMOTER REGIONS, GENETIC; SALMONELLA TYPHIMURIUM; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866341332     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0201     Document Type: Article

References (50)

1. Ellis M, Ding L, Shen D, Luo J, Suman V, Wallis J, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012 Jun 10. [Epub ahead of print].
2. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006;4:61-70.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
4. Gardlik R, Behuliak M, Palffy R, Celec P, Li CJ. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther 2011;18:425-31.
5. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010;10:785-94.
6. Forbes NS, Munn LL, Fukumura D, Jain RK. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 2003;63:5188-93.
7. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A 2005;102:755-60.
8. Ganai S, Arenas RB, Sauer JP, Bentley B, Forbes NS. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther 2011;18:457-66.
9. Kasinskas RW, Forbes NS. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 2007;67:3201-9.
10. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65.
11. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll-and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012;4:120ra116.
12. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7:353-64.
13. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003;4:548-56.
14. McKinney J, Guerrier-Takada C, Galan J, Altman S. Tightly regulated gene expression system in Salmonella enterica serovar typhimurium. J Bacteriol 2002;184:6056-9.
15. Levano-Garcia J, Verjovski-Almeida S, da Silva A. C. Mapping transposon insertion sites by touchdown PCR and hybrid degenerate primers. Biotechniques 2005;38:225-9.
16. Kieboom J, Abee T. Arginine-dependent acid resistance in Salmonella enterica serovar typhimurium. J Bacteriol 2006;188:5650-3.
17. UniProt Consortium. The universal protein resource (UniProt). Nucleic Acids Res 2008;36:D190-5.
18. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
19. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
20. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37-41.
21. O'Loughlin EV, Robins-Browne RM. Effect of Shiga toxin and Shigalike toxins on eukaryotic cells. Microbes Infect 2001;3:493-507.
22. Engedal N, Skotland T, Torgersen ML, Sandvig K. Shiga toxin and its use in targeted cancer therapy and imaging. Microb Biotechnol 2011;4:32-46.
23. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997;57:4537-44.
24. Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004;22:313-20.
25. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001;98:15155-60.
26. Dang LH, Bettegowda C, Agrawal N, Cheong I, Huso D, Frost P, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004;3:326-37.
27. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 2008;10:1235-48.
28. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 2007;297:151-62.
29. Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 2004;101:15172-7.
30. Bettegowda C, Foss CA, Cheong I, Wang Y, Diaz L, Agrawal N, et al. Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluorobeta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A 2005;102:1145-50.
31. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC III, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006;125:385-98.
32. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006;66:7647-52.
33. Leschner S, Deyneko IV, Lienenklaus S, Wolf K, Bloecker H, Bumann D, et al. Identification of tumor-specific Salmonella typhimurium promoters and their regulatory logic. Nucleic Acids Res 2012;40:2984-94.
34. Leschner S, Weiss S. Salmonella-allies in the fight against cancer. J Mol Med (Berl) 2010;88:763-73.
35. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142-52.
36. Heimann DM, Rosenberg SA. Continuous intravenous administration of live genetically modified Salmonella typhimurium in patients with metastatic melanoma. J Immunother 2003;26:179-80.
37. Leschner S, Westphal K, Dietrich N, Viegas N, Jablonska J, Lyszkiewicz M, et al. Tumor invasion of Salmonella enterica serovar typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One 2009;4:e6692.
38. Arrach N, Zhao M, Porwollik S, Hoffman RM, McClelland M. Salmonella promoters preferentially activated inside tumors. Cancer Res 2008;68:4827-32.
39. Hayes ET, Wilks JC, Sanfilippo P, Yohannes E, Tate DP, Jones BD, et al. Oxygen limitation modulates pH regulation of catabolism and hydrogenases, multidrug transporters, and envelope composition in Escherichia coli K-12. BMC Microbiol 2006;6:89.
40. Ibarra JA, Steele-Mortimer O. Salmonella-the ultimate insider. Salmonella virulence factors that modulate intracellular survival. Cell Microbiol 2009;11:1579-86.
41. Foster JW, Spector MP. How Salmonella survive against the odds. Annu Rev Microbiol 1995;49:145-74.
42. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996;56:1194-8.
43. Muller B, Fischer B, Kreutz W. An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells. Immunology 2000;99:375-84.
44. Mukhopadhyay S, Linstedt AD. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012;335:332-5.
45. Flentie KN, Qi M, Gammon ST, Razia Y, Lui F, Marpegan L, et al. Stably integrated luxCDABE for assessment of Salmonella invasion kinetics. Mol Imaging 2008;7:222-33.
46. Pfeifer CG, Marcus SL, Steele-Mortimer O, Knodler LA, Finlay BB. Salmonella typhimurium virulence genes are induced upon bacterial invasion into phagocytic and nonphagocytic cells. Infect Immun 1999;67:5690-8.
47. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005;2:607-14.
48. Rasband W. Image J. 1.3.1-03 ed. Bethesda, MD: NIH; 2005.
49. Zhang XD, Yang XC, Chung N, Gates A, Stec E, Kunapuli P, et al. Robust statistical methods for hit selection in RNA interference high-throughput screening experiments. Pharmacogenomics 2006;7:299-309.
50. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 2000;97:6640-5.